Alphatec's 20% Case Growth Could Not Offset a Biologics Shortfall

Alphatec's third-quarter problem was not a lack of spine surgeries. Case volume rose about 20%, yet revenue increased only 13% to $221 million because the company sold less biologics with each procedure. The mismatch prompted Alphatec to cut its 2026 revenue outlook to about $862 million from $882 million, and the shares fell 36% after the report.

Surgical revenue reached $202 million, up 14% from a year earlier, while surgical hardware revenue grew 17%. New surgeon users increased 25%. Those figures show that more surgeons are using Alphatec's procedural platform, but the company did not convert that activity into the expected amount of revenue. Dividing 14% surgical revenue growth by 20% case growth implies that average surgical revenue per case fell about 5%, a BTI calculation that is consistent with management's explanation of lower biologics attachment.

Biologics are bone-graft products sold alongside spinal implants. Chief Executive Pat Miles said the shortfall was primarily due to lower biologics attachment and called improving that performance a priority. Management also cited slower thoracolumbar procedure volumes, which involve the middle and lower spine, as a possible broader market trend. That second explanation remains unproven until peers report comparable procedure data, so investors should treat it as management's assessment rather than an industry fact.

Profitability improved despite the revenue miss. Alphatec reported a $5 million GAAP net loss, $15 million of non-GAAP net income and $38 million of adjusted EBITDA. The adjusted EBITDA margin reached 17.3%, about four percentage points higher than a year earlier. The company also generated $6 million of free cash flow in the quarter.

The revised full-year outlook calls for about $789 million of surgical revenue and $73 million from EOS imaging, alongside approximately $137 million of adjusted EBITDA. Alphatec now expects about $10 million of free cash flow for 2026. That is a narrow cushion beside the $80 million cash balance at September 30, especially for a company that still needs to support surgeon adoption, inventory and product development.

The next quarter must answer two separate questions. First, can Alphatec restore biologics attachment without slowing case growth? Second, do competing spine companies report the same weakness in thoracolumbar procedures? If peers remain healthy, the evidence would point more strongly to company-specific execution. If the slowdown appears across the sector, Alphatec's growing surgeon base and wider margin could make the selloff look less severe than the operating trend.